Literature DB >> 26402109

Dissociating Statistically-Determined Alzheimer's Disease/Vascular Dementia Neuropsychological Syndromes Using White and Gray Neuroradiological Parameters.

Catherine C Price1, Jared J Tanner1, Ilona M Schmalfuss2,3, Babette Brumback4, Kenneth M Heilman5, David J Libon6.   

Abstract

BACKGROUND: There is remarkable heterogeneity in clinical Alzheimer's disease (AD) or vascular dementia (VaD).
OBJECTIVES: 1) To statistically examine neuropsychological data to determine dementia subgroups for individuals clinically diagnosed with AD or VaD and then 2) examine group differences in specific gray/white matter regions of interest.
METHODS: A k-means cluster analysis requested a 3-group solution from neuropsychological data acquired from individuals diagnosed clinically with AD/VaD. MRI measures of hippocampal, caudate, ventricular, subcortical lacunar infarction, whole brain volume, and leukoaraiosis (LA) were analyzed. Three regions of LA volumes were quantified and these included the periventricular (5 mm around the ventricles), infracortical (5 mm beneath the gray matter), and deep (between periventricular and infracortical) regions.
RESULTS: Cluster analysis sorted AD/VaD patients into single domain amnestic (n = 41), single-domain dysexecutive (n = 26), and multi-domain (n = 26) phenotypes. Multi-domain patients exhibited worst performance on language tests; however, multi-domain patients were equally impaired on memory tests when compared to amnestic patients. Statistically-determined groups dissociated using neuroradiological parameters: amnestic and multi-domain groups presented with smaller hippocampal volume while the dysexecutive group presented with greater deep, periventricular, and whole brain LA. Neither caudate nor lacunae volume differed by group. Caudate nucleus volume negatively correlated with total LA in the dysexecutive and multi-domain groups.
CONCLUSIONS: There are at least three distinct subtypes embedded within patients diagnosed clinically with AD/VaD spectrum dementia. We encourage future research to assess a) the neuroradiological substrates underlying statistically-determined AD/VaD spectrum dementia and b) how statistical modeling can be integrated into existing diagnostic criteria.

Entities:  

Keywords:  Caudate nucleus; Philadelphia (repeatable) Verbal Learning Test; executive function; hippocampus; lacune; learning; leukoaraiosis; memory; ventricles; white matter abnormalities

Mesh:

Year:  2015        PMID: 26402109      PMCID: PMC4724866          DOI: 10.3233/JAD-150407

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  67 in total

1.  Improved optimization for the robust and accurate linear registration and motion correction of brain images.

Authors:  Mark Jenkinson; Peter Bannister; Michael Brady; Stephen Smith
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

Review 2.  Advances in functional and structural MR image analysis and implementation as FSL.

Authors:  Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews
Journal:  Neuroimage       Date:  2004       Impact factor: 6.556

Review 3.  Milestones in Parkinson's disease--clinical and pathologic features.

Authors:  Glenda Halliday; Andrew Lees; Matthew Stern
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

4.  Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.

Authors:  Sylvia Villeneuve; William J Jagust
Journal:  J Prev Alzheimers Dis       Date:  2015-03

5.  Leuko-araiosis: an ancient term for a new problem.

Authors:  V C Hachinski; P Potter; H Merskey
Journal:  Can J Neurol Sci       Date:  1986-11       Impact factor: 2.104

6.  Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease.

Authors:  J Gregor Sutcliffe; Peter B Hedlund; Elizabeth A Thomas; Floyd E Bloom; Brian S Hilbush
Journal:  J Neurosci Res       Date:  2011-03-03       Impact factor: 4.164

Review 7.  The diagnosis and management of mild cognitive impairment: a clinical review.

Authors:  Kenneth M Langa; Deborah A Levine
Journal:  JAMA       Date:  2014-12-17       Impact factor: 56.272

8.  Variability in cognitive presentation of Alzheimer's disease.

Authors:  Cheryl L Stopford; Julie S Snowden; Jennifer C Thompson; David Neary
Journal:  Cortex       Date:  2007-11-17       Impact factor: 4.027

9.  Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease.

Authors:  Christiane Möller; Hugo Vrenken; Lize Jiskoot; Adriaan Versteeg; Frederik Barkhof; Philip Scheltens; Wiesje M van der Flier
Journal:  Neurobiol Aging       Date:  2013-04-03       Impact factor: 4.673

10.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more
  8 in total

1.  Are Parkinson's Patients More Vulnerable to the Effects of Cardiovascular Risk: A Neuroimaging and Neuropsychological Study.

Authors:  Jacob D Jones; Jared J Tanner; Michael Okun; Catherine C Price; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2017-02-06       Impact factor: 2.892

2.  Pilot Investigation: Older Adults With Atrial Fibrillation Demonstrate Greater Brain Leukoaraiosis in Infracortical and Deep Regions Relative to Non-Atrial Fibrillation Peers.

Authors:  Margaret E Wiggins; Jacob Jones; Jared J Tanner; Ilona Schmalfuss; Seyed Hossein Aalaei-Andabili; Kenneth M Heilman; David J Libon; Thomas Beaver; Catherine C Price
Journal:  Front Aging Neurosci       Date:  2020-08-28       Impact factor: 5.750

3.  Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons.

Authors:  Samuel J Crowley; Guita Banan; Manish Amin; Jared J Tanner; Loren Hizel; Peter Nguyen; Babette Brumback; Katie Rodriguez; Nikolaus McFarland; Dawn Bowers; Mingzhou Ding; Thomas A Mareci; Catherine C Price
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

4.  From eyes-closed to eyes-open: Role of cholinergic projections in EC-to-EO alpha reactivity revealed by combining EEG and MRI.

Authors:  Lu Wan; Haiqing Huang; Nadine Schwab; Jared Tanner; Abhijit Rajan; Ngoc B Lam; Laszlo Zaborszky; Chiang-Shan R Li; Catherine C Price; Mingzhou Ding
Journal:  Hum Brain Mapp       Date:  2018-09-25       Impact factor: 5.038

5.  Visual and Verbal Serial List Learning in Patients with Statistically-Determined Mild Cognitive Impairment.

Authors:  Victor Wasserman; Sheina Emrani; Emily F Matusz; David Miller; Kelly Davis Garrett; Katherine A Gifford; Timothy J Hohman; Angela L Jefferson; Rhoda Au; Rod Swenson; David J Libon
Journal:  Innov Aging       Date:  2019-05-03

6.  The Application of Unsupervised Clustering Methods to Alzheimer's Disease.

Authors:  Hany Alashwal; Mohamed El Halaby; Jacob J Crouse; Areeg Abdalla; Ahmed A Moustafa
Journal:  Front Comput Neurosci       Date:  2019-05-24       Impact factor: 2.380

7.  Proof of principle: Preoperative cognitive reserve and brain integrity predicts intra-individual variability in processed EEG (Bispectral Index Monitor) during general anesthesia.

Authors:  Carlos Hernaiz Alonso; Jared J Tanner; Margaret E Wiggins; Preeti Sinha; Hari K Parvataneni; Mingzhou Ding; Christoph N Seubert; Mark J Rice; Cynthia W Garvan; Catherine C Price
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

8.  Identifying and evaluating clinical subtypes of Alzheimer's disease in care electronic health records using unsupervised machine learning.

Authors:  Nonie Alexander; Daniel C Alexander; Frederik Barkhof; Spiros Denaxas
Journal:  BMC Med Inform Decis Mak       Date:  2021-12-08       Impact factor: 2.796

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.